Memory Pharmaceuticals' MEM 1003 failed a Phase IIa study, falling short in demonstrating a statistically significant response for improved symptoms after 12 weeks of therapy among the 183 volunteers in the trial. The volunteers included patients on a monotherapy regimen and subjects on doses of cholinesterase inhibitors. Researchers said that an "unusually large" placebo response led to negative results for the monotherapy group and positive trends but no statistically significant data in the combination group.
- see the Memory release on the trial
Read more on: Alzheimer's